2 results
Approved WMOCompleted
Primary ObjectiveEstimate the proportion of subjects fulfilling criteria for symptomatic remission (as defined by Andreasen et al.)* following a transition to 12 months* treatment with flexible-dose PP3M in subjects with schizophrenia previously…
Approved WMOCompleted
To characterize the exposure-response relationship of MVT-602 effects on luteinizing hormone (LH) concentrations after subcutaneous administration of single 0.1 to 3 µg doses of MVT-602 or placebo in healthy premenopausal women undergoing COS to…